BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Herceptin trastuzumab regulatory update

Roche disclosed in its 4Q10 earnings that last year it submitted a marketing application to China's State Food and Drug Administration (SFDA) for Herceptin trastuzumab to treat advanced HER2-positive gastric cancer. The humanized mAb against epidermal growth factor receptor 2 ( EGFR2; HER2; ErbB2;...

Read the full 234 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >